奥翔药业
(603229)
| 流通市值：80.87亿 | | | 总市值：80.87亿 |
| 流通股本：8.30亿 | | | 总股本：8.30亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 645,961,585.61 | 481,872,188.3 | 306,636,220.57 | 795,288,308.9 |
| 营业收入 | 645,961,585.61 | 481,872,188.3 | 306,636,220.57 | 795,288,308.9 |
| 二、营业总成本 | 436,884,971.86 | 302,198,297.13 | 169,849,438.7 | 575,480,342.93 |
| 营业成本 | 278,241,914.39 | 201,639,220.35 | 119,555,628.58 | 363,980,823.63 |
| 税金及附加 | 6,959,977.9 | 5,313,581.04 | 1,512,984.6 | 11,453,544.14 |
| 销售费用 | 11,369,986.48 | 8,547,536.24 | 3,315,967.99 | 16,754,363.21 |
| 管理费用 | 62,985,906.17 | 38,982,225.37 | 20,819,884.92 | 106,450,831.01 |
| 研发费用 | 81,618,800.72 | 56,338,011.15 | 28,303,999.3 | 100,419,204.52 |
| 财务费用 | -4,291,613.8 | -8,622,277.02 | -3,659,026.69 | -23,578,423.58 |
| 其中:利息费用 | 5,617,852.04 | 3,559,641.71 | 1,699,456.85 | 7,764,497.42 |
| 其中:利息收入 | 14,708,526.34 | 7,687,970.44 | 2,665,455.16 | 20,212,474.49 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 49,477.38 | 545,324.37 | 806,582.36 | 5,499,523.61 |
| 加:投资收益 | 19,243,464.16 | 14,311,078.41 | 5,833,292.85 | 22,864,552.69 |
| 资产减值损失(新) | -1,600,811.6 | -1,600,811.6 | - | -9,406,759.08 |
| 信用减值损失(新) | -1,959,630.61 | -4,814,714.43 | -9,065,194.99 | -7,260,983.68 |
| 其他收益 | 9,424,226.66 | 7,321,484.98 | 2,408,407.73 | 9,639,276.44 |
| 四、营业利润 | 234,233,339.74 | 195,436,252.9 | 136,769,869.82 | 241,143,575.95 |
| 加:营业外收入 | 271,192.69 | 260,842.21 | 260,841.91 | 1,360.78 |
| 减:营业外支出 | 1,158,804.36 | 1,019,641.98 | 298,244.4 | 944,888.08 |
| 五、利润总额 | 233,345,728.07 | 194,677,453.13 | 136,732,467.33 | 240,200,048.65 |
| 减:所得税费用 | 26,313,822.13 | 25,331,346.48 | 17,533,278.56 | 33,409,031.43 |
| 六、净利润 | 207,031,905.94 | 169,346,106.65 | 119,199,188.77 | 206,791,017.22 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 207,031,905.94 | 169,346,106.65 | 119,199,188.77 | 206,791,017.22 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 207,031,905.94 | 169,346,106.65 | 119,199,188.77 | 206,791,017.22 |
| 扣除非经常损益后的净利润 | 183,230,077.39 | 151,121,337.42 | 111,536,167.57 | 178,880,659.45 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.25 | 0.2 | 0.14 | 0.25 |
| (二)稀释每股收益 | 0.25 | 0.2 | 0.14 | 0.25 |
| 八、其他综合收益 | 19,962.48 | 9,445.84 | 670,246.53 | 29,582.57 |
| 归属于母公司股东的其他综合收益 | 19,962.48 | 9,445.84 | 670,246.53 | 29,582.57 |
| 九、综合收益总额 | 207,051,868.42 | 169,355,552.49 | 119,869,435.3 | 206,820,599.79 |
| 归属于母公司股东的综合收益总额 | 207,051,868.42 | 169,355,552.49 | 119,869,435.3 | 206,820,599.79 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-30 | 2025-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |